Results 51 to 60 of about 7,952,783 (243)

Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? [PDF]

, 2017
Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore the theoretical potential to manipulate the inflammatory response to prevent ...
Abbas, Agca, Ait-Oufella, Albert, Alexander, Alexander, Alexander, Alexander, Andersen, Aziz, Babelova, Bellosta, Bevilacqua, Bhaskar, Blom, Boekholdt, Boekholdt, Bostrom, Brånén, Bulgarelli, Bulgarelli, Burke, Cai, Cannon, Casas, Collins, Cronstein, Dahlman-Ghozlan, Danesh, Davenport, Davey Smith, Davidson, DeOliveira, Devlin, Dinarello, Duewell, Duivenvoorden, Eisenhardt, Elango, Elhage, Ettehad, Flood, Fraser, Freigang, Fulgoni, Galkina, Galkina, Garlanda, Grassia, Grassia, Greenberg, Hansson, Hauer, Herder, Holmes, Hu, Huang, Huber, Interleukin 1 Genetics Consortium, Ivandic, Kalliolias, Kaptoge, Kimura, Kinlay, Kirii, Kleinman, Koltsova, Kureishi, Kwak, Lee, Leite, Leite, Lewington, Liao, Libby, Libby, Macritchie, Maddaluno, Maeda, Maffia, Makheja, Margaritis, McInnes, Menu, Micha, Mihaylova, Mira, Mohler, Montezano, Mulhaupt, Murad, Myasoedova, Myung, Nakata, Nicholls, O'Donoghue, Ogdie, Ohta, Pauling, Peters, Qiao, Quarck, Rajamäki, Rastogi, Reiss, Rezaie-Majd, Ridker, Ridker, Rincón, Robertson, Romano, Rosenson, Rosenson, Roubille, Ryan, Rössig, Saeed, Sage, Sarwar, Sattar, Scalia, Schett, Schieffer, Schuett, Serruys, Sever, Sever, Shah, Shaposhnik, Singh, Sirtori, Sniderman, Soedamah-Muthu, Solomon, Southan, Souverein, Sprague, Srikakulapu, Strober, Sukovich, Swerdlow, Swirski, Talmud, Tay, Teng, Thompson, Tits, Toedter, Turunen, Tzellos, Walker, Wang, Wang, Watson, Weintraub, Welsh, Welsh, Welsh, Welsh, Weng, Wensley, White, Wilensky, Willeit, Willis, Wong, Woodward, Xanthoulea, Ye, Ye, Yilmaz, Youssef, Zalewski, Zhao   +173 more
core   +2 more sources

Vascular Targeting in Pancreatic Cancer: The Novel Tubulin-Binding Agent ZD6126 Reveals Antitumor Activity in Primary and Metastatic Tumor Models

Neoplasia: An International Journal for Oncology Research, 2005
ZD6126 is a novel vascular-targeting agent that acts by disrupting the tubulin cytoskeleton of an immature tumor endothelium, leading to an occlusion of tumor blood vessels and a subsequent tumor necrosis.
Axel Kleespies, Gudrun Köhl, Michael Friedrich, Anderson J. Ryan, Alan Barge, Karl-Walter Jauch, Christiane J. Bruns   +6 more
doaj   +1 more source

Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin

eLife, 2020
Edema stemming from leaky blood vessels is common in eye diseases such as age-related macular degeneration and diabetic retinopathy. Whereas therapies targeting vascular endothelial growth factor A (VEGFA) can suppress leakage, side-effects include ...
Ross O Smith, Takeshi Ninchoji, Emma Gordon, Helder André, Elisabetta Dejana, Dietmar Vestweber, Anders Kvanta, Lena Claesson-Welsh   +7 more
doaj   +1 more source

Early diagnosis of bladder cancer by photoacoustic imaging of tumor-targeted gold nanorods

Photoacoustics, 2022
Detection and removal of bladder cancer lesions at an early stage is crucial for preventing tumor relapse and progression. This study aimed to develop a new technological platform for the visualization of small and flat urothelial lesions of high-grade ...
Elisa Alchera, Matteo Monieri, Mirko Maturi, Irene Locatelli, Erica Locatelli, Silvia Tortorella, Angelina Sacchi, Angelo Corti, Manuela Nebuloni, Roberta Lucianò, Filippo Pederzoli, Francesco Montorsi, Andrea Salonia, Sandra Meyer, Jithin Jose, Pierangela Giustetto, Mauro Comes Franchini, Flavio Curnis, Massimo Alfano   +18 more
doaj   +1 more source

Vascular targeted therapies in oncology [PDF]

Cell and Tissue Research, 2008
Neovascularization is intimately involved in tumor survival, progression, and spread, factors known to contribute significantly to treatment failures. Thus, strategies targeting the tumor blood vessel support network may offer not only unique therapeutic opportunities in their own right, but also novel means of enhancing the efficacies of conventional ...
Siemann, Dietmar W, Horsman, Michael R
openaire   +2 more sources

Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells [PDF]

, 2016
Indexación: Web of ScienceTumor angiogenesis is widely recognized as one of the hallmarks of cancer. Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and ...
Carrasco-Avino, G, Corvalan, AH, Owen, GI, Pinto, MP, Sotomayor, P   +4 more
core   +1 more source

Exploring the perspectives of pharmaceutical experts and healthcare practitioners on senolytic drugs for vascular aging-related disorder: a qualitative study

Frontiers in Pharmacology, 2023
Objective: The field of targeting cellular senescence with drug candidates to address age-related comorbidities has witnessed a notable surge of interest and research and development.
Li Ping Wong, Li Ping Wong, Haridah Alias, Kit Mun Tan, Pooi Fong Wong, Dharmani Devi Murugan, Zhijian Hu, Yulan Lin   +7 more
doaj   +1 more source

Why one-size-fits-all vaso-modulatory interventions fail to control glioma invasion: in silico insights

, 2016
There is an ongoing debate on the therapeutic potential of vaso-modulatory interventions against glioma invasion. Prominent vasculature-targeting therapies involve functional tumour-associated blood vessel deterioration and normalisation. The former aims
Alfonso, J. C. L., Deutsch, A., Feuerhake, F., Hatzikirou, H., Kohn-Luque, A., Stylianopoulos, T.   +5 more
core   +1 more source

Blood-brain barrier dysfunction in ischemic stroke: targeting tight junctions and transporters for vascular protection.

American Journal of Physiology - Cell Physiology, 2018
The blood-brain barrier (BBB) is a physical and biochemical barrier that precisely controls cerebral homeostasis. It also plays a central role in the regulation of blood-to-brain flux of endogenous and exogenous xenobiotics and associated metabolites ...
Wazir Abdullahi, D. Tripathi, P. Ronaldson   +2 more
semanticscholar   +1 more source

GBM radiosensitizers: dead in the water…or just the beginning? [PDF]

, 2017
The finding that most GBMs recur either near or within the primary site after radiotherapy has fueled great interest in the development of radiosensitizers to enhance local control.
Bindra, Ranjit S., Chalmers, Anthony J., Dewhirst, Mark, Evans, Sydney   +3 more
core   +1 more source